Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GlucoTrack, Inc. (GCTK)
USD0.63
+0.10 (+18.71%)
IL NASDAQ Healthcare Medical - Instruments & Supplies
Address
8 Ariel Sharon Street 7760049
Or Yehuda, IL
Or Yehuda, IL
CEO
Paul V. Goode
Website
glucotrack.com
IPO
2013-04-25
CIK 1506983 ISIN US45824Q8042
Also trades on
NASDAQ Capital Market · GCTK (USD)
NASDAQ Capital Market · IGAP (USD)
Description
Based in Or Yehuda, Israel, GlucoTrack, Inc. is a medical technology company focused on innovating, developing, and bringing to market non-invasive glucose monitoring systems. Their primary offering, the GlucoTrack device, enables individuals with diabetes or pre-diabetes to painlessly check their blood glucose levels. This technology is available to customers both in Israel and across the globe. The company, founded in 2001, operated under the name Integrity Applications, Inc. until it officially rebranded to GlucoTrack, Inc. in November 2021.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.63
+0.10 (+18.71%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
0.76
Float Shares
565.4K
Free Float %
99.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.97% | -15.77% | -18.65% | -62.21% | -87.50% | -83.20% | -92.53% | -99.98% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.63
DCF (Unlevered)
6.81
+984.6%
DCF (Levered)
8.17
+1,201.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
-56.58
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%—
-
EPS growth Medical - Instruments & Supplies: +16.3%-135.5% Q1'26: +106.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%—
-
EBIT margin Medical - Instruments & Supplies: +13.5%—
-
ROIC Medical - Instruments & Supplies: +6.0%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+141.8% Q1'26: +340.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-16.35M
OE per share TTM
-19.56
Owner's Yield
-1,535.43%
Maintenance CapEx ratio
0.00%
Maint CapEx / Avg PPE
547.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
15
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JOHN A BALLANTYNE | 66.30M | 33.26% | — | — | 17.4K | 10.00 | IN | or Place of Organization | 2020-02-25 | ↗ |
| 2 | JOHN A BALLANTYNE REV TRUST 08/01/2017 | 66.28M | 33.25% | — | — | — | 10.00 | OO | or Place of Organization | 2020-02-25 | ↗ |
| 3 | John Ballantyne | 657.0K | 9.90% | 657.0K | — | 657.0K | — | IN | Mr. Ballantyne is a citizen of New Zealand and a permanent resident of the United States. | 2017-03-20 | ↗ |
| 4 | Avner Gal | 450.5K | 7.70% | 450.5K | — | 450.5K | — | IN | Israel | 2016-02-16 | ↗ |
| 5 | Philip M. Darivoff | 398.5K | 7.30% | — | 398.5K | — | — | IN | Mr. Darivoff is a citizen of the United States. | 2013-02-14 | ↗ |
| 6 | Vayikra Capital, LLC | 398.5K | 7.30% | 398.5K | — | 398.5K | — | OO | Delaware | 2013-02-14 | ↗ |
| 7 | Amos and Daughters Investments and Properties Ltd. | 393.7K | 7.20% | 393.7K | — | 393.7K | — | OO | Israel | 2013-02-14 | ↗ |
| 8 | Arza Steimatzky | 393.7K | 7.20% | — | 393.7K | — | — | IN | Ms. Steimatzky is a citizen of Israel. | 2013-02-14 | ↗ |
| 9 | Ella Steimatzky | 393.7K | 7.20% | — | 393.7K | — | — | IN | Ms. Steimatzky is a citizen of Israel. | 2013-02-14 | ↗ |
| 10 | Eri Steimatzky | 393.7K | 7.20% | — | 393.7K | — | — | IN | Mr. Steimatzky is a citizen of Israel. | 2013-02-14 | ↗ |
| 11 | Osnat Steimatzky | 393.7K | 7.20% | — | 393.7K | — | — | IN | Ms. Steimatzky is a citizen of Israel. | 2013-02-14 | ↗ |
| 12 | Rachel Steimatsky | 393.7K | 7.20% | — | 393.7K | — | — | IN | Mrs. Steimatsky is a citizen of Israel. | 2013-02-14 | ↗ |
| 13 | Zvi Cohen | 361.7K | 6.60% | 361.7K | — | 361.7K | — | IN | Israel | 2013-02-14 | ↗ |
| 14 | Drew Sycoff | 321.3K | 5.86% | 321.3K | — | 321.3K | — | IN | - USA | 2024-09-10 | ↗ |
| 15 | Joel Gold | 318.4K | 5.80% | 100.2K | 218.3K | 100.2K | — | IN | United States | 2013-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
7.5K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+7,486
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-03 | Malave Luis | Director | A-Award | A | Common Stock, par value $0.001 per share | 463 | 0.00 | — | 4,058 | D | ↗ |
| 2025-10-03 | Carter Erin Catherine | Director | A-Award | A | Stock option (right to buy) | 4,055 | 7.40 | 30.0K | 4,055 | D | ↗ |
| 2025-10-03 | Balo Andrew K | Director | A-Award | A | Common Stock, par value $0.001 per share | 1,285 | 0.00 | — | 4,692 | D | ↗ |
| 2025-07-11 | Malave Luis | Director | A-Award | A | Common Stock, par value $0.001 per share | 1,200 | 0.00 | — | 3,595 | D | ↗ |
| 2025-07-11 | Carter Erin Catherine | Director | A-Award | A | Common Stock, par value $0.001 per share | 1,000 | 0.00 | — | 1,762 | D | ↗ |
| 2025-07-11 | Balo Andrew K | Director | A-Award | A | Common Stock, par value $0.001 per share | 3,332 | 0.00 | — | 3,407 | D | ↗ |
| 2025-05-22 | CARR BRENDEL VICTORIA | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-26 | Malave Luis | Director | A-Award | A | Common Stock, par value $0.001 per share | 2,076 | 0.00 | — | 143,617 | D | ↗ |
| 2025-03-26 | Fischell Robert | Director | A-Award | A | Common Stock, par value $0.001 per share | 1,498 | 0.00 | — | 2,045 | D | ↗ |
| 2025-03-26 | Danzig Allen | Director | A-Award | A | Common Stock, par value $0.001 per share | 1,498 | 0.00 | — | 1,922 | D | ↗ |
| 2025-03-26 | Carter Erin Catherine | Director | A-Award | A | Common Stock, par value $0.001 per share | 1,896 | 0.00 | — | 45,632 | D | ↗ |
| 2025-03-26 | Balo Andrew K | Director | A-Award | A | Common Stock, par value $0.001 per share | 4,490 | 0.00 | — | 4,490 | D | ↗ |
| 2025-03-26 | BALLANTYNE JOHN | Director / 10% Owner | A-Award | A | Common Stock, par value $0.001 per share | 4,126 | 0.00 | — | 4,126 | D | ↗ |
| 2025-03-25 | Malave Luis | Director | A-Award | A | Common Stock, par value $0.001 per share | 35 | 0.00 | — | 2,395 | D | ↗ |
| 2025-03-25 | Goode Paul | Director / Officer | J-Other | A | Common Stock, par value $0.001 per share | 42 | 0.00 | 0.04 | 339 | D | ↗ |
| 2025-03-25 | Carter Erin Catherine | Director | A-Award | A | Common Stock, par value $0.001 per share | 32 | 0.00 | — | 762 | D | ↗ |
| 2025-03-25 | Balo Andrew K | Director | A-Award | A | Common Stock, par value $0.001 per share | 75 | 0.00 | — | 75 | D | ↗ |
| 2025-03-12 | Malave Luis | Director | X-InTheMoney | A | Common Stock, par value $0.001 per share | 133,532 | 0.00 | — | 141,541 | D | ↗ |
| 2025-03-12 | John A. Ballantyne Revocable Living Trust dated 08/01/2017 | 10% Owner | X-InTheMoney | D | Series B Common Warrant | 132,036 | 0.00 | — | 0 | D | ↗ |
| 2025-03-12 | Goode Paul | Director / Officer | X-InTheMoney | A | Common Stock, par value $0.001 per share | 15,435 | 0.00 | — | 18,989 | D | ↗ |
| 2025-03-12 | Carter Erin Catherine | Director | X-InTheMoney | A | Common Stock, par value $0.001 per share | 40,297 | 0.00 | — | 43,736 | D | ↗ |
| 2025-03-12 | BALLANTYNE JOHN | Director / 10% Owner | X-InTheMoney | A | Common Stock, par value $0.001 per share | 2,560,553 | 0.00 | — | 2,743,591 | I | ↗ |
| 2025-02-05 | Goode Paul | Director / Officer | J-Other | A | Common Stock, par value $0.001 per share | 1,500 | 0.00 | — | 3,554 | D | ↗ |
| 2025-01-28 | Wulff Peter C | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-11-14 | Malave Luis | Director | C-Conversion | D | Convertible Promissory Note | 0 | 31.20 | — | 0 | D | ↗ |
| 2024-11-14 | John A. Ballantyne Revocable Living Trust dated 08/01/2017 | 10% Owner | J-Other | A | Common Stock, par value $0.001 per share | 132,036 | 31.00 | 4.09M | 183,039 | D | ↗ |
| 2024-11-14 | Goode Paul | Director / Officer | C-Conversion | A | Common Stock, par value $0.001 per share | 796 | 31.20 | 24.8K | 2,054 | D | ↗ |
| 2024-11-14 | Carter Erin Catherine | Director | C-Conversion | A | Convertible Promissory Note | 0 | 31.20 | — | 0 | D | ↗ |
| 2024-11-14 | BALLANTYNE JOHN | Director / 10% Owner | A-Award | A | Series B Common Warrant | 132,036 | 5.60 | 739.4K | 132,036 | I | ↗ |
| 2024-08-16 | BALLANTYNE JOHN | Director / 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 1,020,033 | I | ↗ |
| 2024-07-30 | John A. Ballantyne Revocable Living Trust dated 08/01/2017 | 10% Owner | — | — | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 51,002 | D | ↗ |
| 2024-07-30 | BALLANTYNE JOHN | Director / 10% Owner | P-Purchase | A | Warrants to Purchase Common Stock | 106,667 | 37.50 | 4.00M | 106,667 | I | ↗ |
| 2024-07-18 | Malave Luis | Director | P-Purchase | A | Convertible Promissory Note | 0 | 31.20 | — | 0 | D | ↗ |
| 2024-07-18 | Goode Paul | Director / Officer | P-Purchase | A | Convertible Promissory Note | 0 | 31.20 | — | 0 | D | ↗ |
| 2024-07-18 | Carter Erin Catherine | Director | P-Purchase | A | Convertible Promissory Note | 0 | 31.20 | — | 0 | D | ↗ |
| 2024-07-01 | SYCOFF DREW | Director / 10% Owner | P-Purchase | A | Warrants to Purchase Common Stock | 138,000 | 4.95 | 683.1K | 138,000 | — | ↗ |
| 2024-07-01 | Goode Paul | Officer | P-Purchase | A | Warrants to Purchase Common Stock | 42,000 | 4.95 | 207.9K | 42,000 | — | ↗ |
| 2024-06-14 | Goode Paul | Director / Officer | A-Award | A | Stock option (right to buy) | 3,277 | 49.00 | 160.6K | 3,277 | D | ↗ |
| 2024-06-14 | Balo Andrew K | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-04-22 | SYCOFF DREW | Director / 10% Owner | P-Purchase | A | Common Stock | 182,540 | 1.26 | 230.0K | 2,951,258 | — | ↗ |
| 2024-04-22 | Goode Paul | Officer | — | D | Common Stock | 0 | 0.00 | — | 398,820 | — | ↗ |
| 2024-04-08 | Malave Luis | Director | A-Award | A | Common Stock, par value $0.001 per share | 489 | 0.00 | — | 1,123 | D | ↗ |
| 2024-04-08 | Fischell Robert | Director | A-Award | A | Common Stock, par value $0.001 per share | 229 | 0.00 | — | 547 | D | ↗ |
| 2024-04-08 | Danzig Allen | Director | A-Award | A | Common Stock, par value $0.001 per share | 229 | 0.00 | — | 424 | D | ↗ |
| 2024-04-08 | Carter Erin Catherine | Director | A-Award | A | Common Stock, par value $0.001 per share | 458 | 0.00 | — | 1,361 | D | ↗ |
| 2023-12-31 | Malave Luis | Director | A-Award | A | Common Stock, par value $0.001 per share | 362 | 0.00 | — | 634 | D | ↗ |
| 2023-12-31 | Carter Erin Catherine | Director | A-Award | A | Common Stock, par value $0.001 per share | 903 | 0.00 | — | 903 | D | ↗ |
| 2023-10-11 | Cardwell James S | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-25 | Carter Erin Catherine | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-04-20 | Malave Luis | Director | A-Award | A | Common Stock, par value $0.001 per share | 121 | 0.00 | — | 272 | D | ↗ |
| 2023-01-09 | Malave Luis | Director | A-Award | A | Common Stock, par value $0.001 per share | 29 | 0.00 | — | 151 | D | ↗ |
| 2022-10-04 | Malave Luis | Director | A-Award | A | Common Stock, par value $0.001 per share | 44 | 0.00 | — | 122 | D | ↗ |
| 2022-10-04 | Danzig Allen | Director | A-Award | A | Common Stock, par value $0.001 per share | 44 | 0.00 | — | 195 | D | ↗ |
| 2022-06-30 | Malave Luis | Director | A-Award | A | Common Stock, par value $0.001 per share | 34 | 0.00 | — | 78 | D | ↗ |
| 2022-05-17 | Danzig Allen | Director | — | D | Common Stock | 0 | 0.00 | — | 15,048 | — | ↗ |
| 2022-03-31 | Malave Luis | Director | A-Award | A | Common Stock, par value $0.001 per share | 25 | 0.00 | — | 44 | D | ↗ |
| 2021-12-31 | Malave Luis | Director | A-Award | A | Common Stock, par value $0.001 per share | 11 | 0.00 | — | 19 | D | ↗ |
| 2021-09-30 | Malave Luis | Director | A-Award | A | Common Stock, par value $0.001 per share | 8 | 0.00 | — | 8 | D | ↗ |
| 2021-08-24 | Fischell Robert | Director | A-Award | A | Common Stock, par value $0.001 per share | 318 | 0.00 | — | 318 | D | ↗ |
| 2021-06-22 | Malave Luis | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-07-30 | Rapps Shimon D | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-07-08 | SYCOFF DREW | Director | — | I | Common Stock | 0 | 0.00 | — | 952,454 | — | ↗ |
| 2019-07-01 | SYCOFF DREW | Director | — | I | Warrant | 108,305 | 3.60 | 389.9K | 0 | — | ↗ |
| 2017-06-26 | podwalski david | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-06-01 | Seff Leslie | Director | A-Award | A | Restricted Stock Units | 22,727 | 0.00 | — | 22,727 | — | ↗ |
| 2017-06-01 | SCHWARTZ REVAN | Director | A-Award | A | Restricted Stock Units | 22,727 | 0.00 | — | 22,727 | — | ↗ |
| 2017-06-01 | Hauck Michael | Director | A-Award | A | Restricted Stock Units | 22,727 | 0.00 | — | 22,727 | — | ↗ |
| 2017-06-01 | Fischell Robert | Director | A-Award | A | Restricted Stock Units | 22,727 | 0.00 | — | 22,727 | — | ↗ |
| 2017-06-01 | BOYDSTON ANGELA STRAND | Director / Officer | A-Award | A | Restricted Stock Units | 25,252 | 0.00 | — | 25,252 | — | ↗ |
| 2017-05-23 | Hauck Michael | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-04-13 | Malka David | Officer | A-Award | A | Option (Right to Buy) | 25,000 | 4.50 | 112.5K | 25,000 | — | ↗ |
| 2017-03-20 | Seff Leslie | Director | A-Award | A | Common Stock, par value $0.001 per share | 3,334 | 0.00 | — | 3,334 | — | ↗ |
| 2017-03-20 | GRAHAM JOHN A | Director / Officer | A-Award | A | Option (Right to Buy) | 844,130 | 7.75 | 6.54M | 844,130 | — | ↗ |
| 2017-03-20 | BOYDSTON ANGELA STRAND | Director | A-Award | A | Common Stock, par value $0.001 per share | 4,445 | 0.00 | — | 4,445 | — | ↗ |
| 2017-03-08 | Darivoff Philip | Director | P-Purchase | A | Series C 5.5% Convertible Preferred Stock | 1,000 | 4.50 | 4.5K | 1,000 | — | ↗ |
| 2017-01-31 | SASSOUN SAMI | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-11-30 | Darivoff Philip | Director | P-Purchase | A | Series C-1 Warrants | 66,667 | 4.50 | 300.0K | 66,667 | — | ↗ |
| 2016-11-15 | SCHWARTZ REVAN | Director | A-Award | A | Options (Right to Buy) | 26,666 | 4.50 | 120.0K | 26,666 | — | ↗ |
| 2016-11-15 | Darivoff Philip | Director | A-Award | A | Options (Right to Buy) | 26,666 | 4.50 | 120.0K | 26,666 | — | ↗ |
| 2016-11-09 | SCHWARTZ REVAN | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-11-09 | Darivoff Philip | Director | — | I | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 414,372 | — | ↗ |
| 2016-03-23 | Seff Leslie | Director | A-Award | A | Option (Right to Buy) | 26,666 | 4.50 | 120.0K | 26,666 | — | ↗ |
| 2016-03-23 | BOYDSTON ANGELA STRAND | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-03-17 | Fischell Robert | Director | A-Award | A | Option (Right to buy) | 26,666 | 4.50 | 120.0K | 26,666 | — | ↗ |
| 2015-03-11 | Malka David | Director / Officer | J-Other | D | Common Stock, par value $0.001 per share | 61,471 | 0.00 | — | 123,695 | — | ↗ |
| 2015-03-11 | Gal Avner | Director / Officer | J-Other | D | Common Stock, par value $0.001 per share | 136,162 | 0.00 | — | 273,989 | — | ↗ |
| 2015-03-11 | Cohen Zvi | Director | J-Other | D | Common Stock, par value $0.001 per share | 120,077 | 0.00 | — | 241,625 | — | ↗ |
| 2015-01-01 | Darivoff Philip | Director | — | I | Series B-2 Warrant | 0 | 10.00 | — | 0 | — | ↗ |
| 2014-09-30 | Hertz Eran | Officer | A-Award | A | Employee stock option (right to buy) | 10,000 | 7.00 | 70.0K | 10,000 | — | ↗ |
| 2013-11-17 | Hertz Eran | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-02-24 | Ehrlich Israel B. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-08-14 | Malka David | Director / Officer | — | D | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 185,166 | — | ↗ |
| 2012-08-14 | Gold Joel L | Director | — | I | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 218,280 | — | ↗ |
| 2012-08-14 | Gal Avner | Director / Officer | — | D | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 410,151 | — | ↗ |
| 2012-08-14 | Fischell Robert | Director | — | D | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 48,000 | — | ↗ |
| 2012-08-14 | Cohen Zvi | Director | — | D | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 361,702 | — | ↗ |
| 2012-08-14 | Bar-Shalom Jacob | Officer | — | D | Option (Right to Buy) | 10,000 | 6.25 | 62.5K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
567.5K
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Paul V Goode Chief Executive Officer | 350.0K | — | — | — | — | — | 350.0K | 0.00% | ↗ |
| 2 | 2023 | Paul V Goode Chief Executive Officer | 225.0K | — | — | 258.2K | — | — | 356.2K | 72.49% | ↗ |
| 3 | 2023 | James Thrower Vice President of Engineering | 230.0K | — | 34.1K | — | — | — | 264.1K | 12.92% | ↗ |
| 4 | 2023 | Jolie Kahn Chief Financial Officer | 135.0K | — | — | — | — | 98.5K | 233.5K | 0.00% | ↗ |
| 5 | 2023 | Mark Tapsak, PhD Vice President of Technology | 165.0K | — | 11.2K | — | — | — | 176.2K | 6.36% | ↗ |
| 6 | 2022 | Paul Goode Chief Executive Officer | 200.6K | — | — | 263.8K | — | 21.3K | 485.7K | 54.31% | ↗ |
| 7 | 2022 | Paul V Goode Chief Executive Officer | 200.6K | — | 318.3K | — | — | 21.3K | 485.7K | 65.55% | ↗ |
| 8 | 2022 | James Thrower Chief Technology Officer | 230.0K | — | — | 92.9K | — | 38.5K | 361.4K | 25.71% | ↗ |
| 9 | 2022 | James Thrower Vice President of Engineering | 230.0K | — | 92.9K | — | — | 38.5K | 361.4K | 25.71% | ↗ |
| 10 | 2022 | Jolie Kahn Chief Financial Officer | 120.0K | — | — | — | — | — | 120.0K | 0.00% | ↗ |
| 11 | 2022 | Erez Ben Zvi General Manager and VP of Product (resigned June 26, 2022) | 84.2K | — | — | 3.0K | — | 23.0K | 110.2K | 2.74% | ↗ |
| 12 | 2022 | Shalom Shushan Chief Technology Officer (resigned May 22, 2022) | 84.4K | — | — | 2.1K | — | 22.6K | 109.1K | 1.88% | ↗ |
| 13 | 2022 | Mark Tapsak, PhD Vice President of Technology | 41.3K | — | 5.4K | — | — | — | 46.7K | 11.60% | ↗ |
| 14 | 2021 | Erez Ben Zvi General Manager and VP of Product (resigned June 26, 2022) | 183.3K | — | — | 76.2K | — | 48.6K | 308.1K | 24.74% | ↗ |
| 15 | 2021 | Shalom Shushan Chief Technology Officer (resigned May 22, 2022) | 203.1K | — | — | 22.2K | — | 58.9K | 284.3K | 7.81% | ↗ |
| 16 | 2021 | Jolie Kahn Chief Financial Officer | 120.0K | — | — | — | — | — | 120.0K | 0.00% | ↗ |
| 17 | 2019 | David Podwalski Former President David Malka Eugene Naidis Vice President of R&D | 206.3K | — | — | — | — | 34.4K | 240.7K | 0.00% | ↗ |
| 18 | 2018 | David Podwalski Former President David Malka Eugene Naidis Vice President of R&D | 110.0K | — | — | 131.3K | — | 50.2K | 291.5K | 45.05% | ↗ |
| 19 | 2017 | John Graham Chief Executive Officer | 266.4K | 375.0K | — | 1.59M | — | — | 2.23M | 71.26% | ↗ |
| 20 | 2017 | David Malka Vice President of Operations | 105.0K | — | — | 110.9K | — | 67.4K | 283.3K | 39.15% | ↗ |
| 21 | 2017 | Sami Sassoun Chief Financial Officer | 109.3K | — | — | 82.4K | — | 64.0K | 255.7K | 32.24% | ↗ |
| 22 | 2017 | Eugene Naidis Vice President of R&D | 96.4K | — | — | 82.4K | — | 49.3K | 228.2K | 36.13% | ↗ |
| 23 | 2017 | David Podwalski Chief Commercialization Officer | 94.5K | — | — | 130.8K | — | — | 225.4K | 58.05% | ↗ |
| 24 | 2016 | Eugene Naidis Vice President of R&D | 79.7K | — | — | — | — | 40.8K | 120.4K | 0.00% | ↗ |
| 25 | 2016 | David Malka Vice President of Operations | 63.1K | — | — | — | — | 48.0K | 111.2K | 0.00% | ↗ |
| 26 | 2014 | Chief Executive Officer | 134.8K | — | — | — | — | 109.1K | 243.9K | 0.00% | ↗ |
| 27 | 2014 | Chief Financial Officer | 93.3K | — | — | — | — | 53.3K | 146.6K | 0.00% | ↗ |
| 28 | 2014 | Executive Vice President of Operations | 67.3K | — | — | — | — | 54.8K | 122.1K | 0.00% | ↗ |
| 29 | 2013 | Chief Executive Officer | 134.1K | 61.1K | — | — | — | 59.2K | 254.4K | 0.00% | ↗ |
| 30 | 2013 | Executive Vice President of Operations | 66.6K | 30.5K | — | — | — | 72.1K | 169.3K | 0.00% | ↗ |
| 31 | 2013 | Chief Financial Officer | 67.8K | — | — | 9.2K | — | 42.1K | 119.2K | 7.74% | ↗ |
| 32 | 2012 | Avner Gal Chief Executive Officer | 163.8K | — | — | 252.0K | — | 19.9K | 435.8K | 57.84% | ↗ |
| 33 | 2012 | Chief Executive Officer | 125.5K | — | — | — | — | 55.2K | 432.7K | 0.00% | ↗ |
| 34 | 2012 | David Malka Executive Vice President of Operations | 85.9K | — | — | 75.6K | — | 19.3K | 180.8K | 41.82% | ↗ |
| 35 | 2012 | Executive Vice President of Operations | 62.8K | — | — | — | — | 42.4K | 180.8K | 0.00% | ↗ |
| 36 | 2012 | Jacob Bar-Shalom Chief Financial Officer | 80.3K | — | — | 12.8K | — | 9.2K | 102.3K | 12.53% | ↗ |
| 37 | 2012 | Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 38 | 2011 | Avner Gal Chief Executive Officer | 180.1K | — | — | 218.1K | — | 17.3K | 415.5K | 52.50% | ↗ |
| 39 | 2011 | David Malka Executive Vice President of Operations | 91.8K | — | — | 65.4K | — | 21.2K | 178.4K | 36.67% | ↗ |
| 40 | 2011 | Jacob Bar-Shalom Chief Financial Officer | 27.1K | — | — | — | — | 56.0K | 83.1K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Paul V. Goode | Chief Executive Officer, President & Director | 394.1K | male |
| David Malka | Co-Founder | 191.9K | male |
| Avner Gal MSc.EE | Co-Founder, Chairman Emeritus, Consultant and Member of Scientific & Clinical Advisory Board | 187.4K | male |
| Mark Tapsak | Chief Scientific Officer | 165.0K | male |
| Drinda Benjamin | Vice President of Marketing | — | female |
| Peter C. Wulff | Chief Financial Officer, Treasurer & Secretary | — | male |
| Vincent Wong | Chief Operations Officer | — | male |
ESG Rating
ESG Score History MEDICAL - INSTRUMENTS & SUPPLIES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GCTK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
